| Browse All

Revolution Medicines, Inc. (RVMDW)

Redwood City, United States | NasdaqGS
5.43 USD -0.08 (-1.452%) ⇩ (April 17, 2026, 3:57 p.m. EDT)

Short-term: ☆☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 18, 2026, 10:07 p.m. EDT

CRITICAL LORAX DOWNSIDE: 17.64 million shares (Dir sale) combined with massive negative free cash flow (-$523M FCFF, -$897M OCF) and zero recent price movement after hitting $5.77 high. Sponsor holding (W) trapped at near-block bottom.

None
Attribute Value
Debt to Equity Ratio 26.185
Beta 1.01
Website https://www.revmed.com

Info Dump

Attribute Value
Address1 700 Saginaw Drive
Ask 0.3899
Ask Size 2
Beta 1.012
Bid 0.3517
Bid Size 20
Book Value 8.281
City Redwood City
Compensation As Of Epoch Date 1,735,603,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 5.43
Current Ratio 7.145
Custom Price Alert Confidence HIGH
Day High 5.77
Day Low 5.21
Debt To Equity 26.185
Display Name Revolution Medicines
Ebitda -1,174,619,008
Ebitda Margins 0.0
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Two Week High 5.77
Fifty Two Week High Change -0.34000015
Fifty Two Week High Change Percent -0.058925502
Fifty Two Week Low 5.21
Fifty Two Week Low Change 0.21999979
Fifty Two Week Low Change Percent 0.04222645
Fifty Two Week Range 5.21 - 5.77
Financial Currency USD
First Trade Date Milliseconds 1,772,807,400,000
Float Shares 178,734,568
Free Cashflow -523,279,008
Full Exchange Name NasdaqGS
Full Time Employees 883
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Gross Profits -987,331,968
Has Pre Post Market Data 1
Industry
Industry Key
Ipo Expected Date 2,023-11-17
Language en-US
Long Business Summary Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Long Name Revolution Medicines, Inc.
Market us_market
Market State CLOSED
Max Age 86,400
Message Board Id finmb_283775412
Net Income To Common -1,131,300,992
Open 0.386
Operating Cashflow -897,740,992
Operating Margins 0.0
Phone 650 481 6801
Previous Close 5.51
Price Hint 2
Price To Book 0.65571785
Profit Margins 0.0
Quick Ratio 6.975
Quote Source Name Delayed Quote
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.0800004
Regular Market Change Percent -1.4519128
Regular Market Day High 5.77
Regular Market Day Low 5.21
Regular Market Day Range 5.21 - 5.77
Regular Market Open 0.386
Regular Market Previous Close 5.51
Regular Market Price 5.43
Regular Market Time 1,776,455,839
Regular Market Volume 140,460
Return On Assets -0.30084
Return On Equity -0.58068
Sand P52 Week Change 0.38150132
Sector
Sector Key
Short Name Revolution Medicines, Inc. Warr
Source Interval 15
State CA
Symbol RVMDW
Total Cash 2,025,678,976
Total Cash Per Share 10.222
Total Debt 427,148,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Peg Ratio None
Triggerable 1
Type Disp Equity
Volume 140,460
Website https://www.revmed.com
Zip 94,063